Evotec announces deal to expand HIV antibody production

 

BERLIN – German biotechnology company Evotec SE   on Wednesday announced  that it is expanding its partnership with ADAdvanced BioScience Laboratories (ABL) to advance manufacturing processes for HIV neutralizing antibodies.

The deal involved its Seattle unit Just-Evotec Biologics, it said. The financial details of the agreement were not yet disclosed.

Under the terms, Just-Evotec Biologics will develop a third broadly neutralizing HIV-1 antibody (bNAb) and perform large-scale current good manufacturing practice (cGMP) manufacturing campaigns for the current bNAb and a previously developed bNAb against HIV along with providing release and stability testing services.

According to World Health Organization (WHO), 38 million individuals live with HIV globally.

Both the companies aim to supply clinical material to continue vital ongoing clinical trials worldwide through this programme.

On Tuesday, Evotec shares closed at €14.13 ($15.21), up 6.64% in Germany.